Top

Diabetologia

Published in:

01-02-2011 | Article

Deletion of protein kinase Cδ in mice modulates stability of inflammatory genes and protects against cytokine-stimulated beta cell death in vitro and in vivo

Authors: J. Cantley, E. Boslem, D. R. Laybutt, D. V. Cordery, G. Pearson, L. Carpenter, M. Leitges, T. J. Biden

Published in: Diabetologia | Issue 2/2011

Abstract

Aims/hypothesis

Proinflammatory cytokines contribute to beta cell destruction in type 1 diabetes, but the mechanisms are incompletely understood. The aim of the current study was to address the role of the protein kinase C (PKC) isoform PKCδ, a diverse regulator of cell death, in cytokine-stimulated apoptosis in primary beta cells.

Methods

Islets isolated from wild-type or Prkcd ^−/− mice were treated with IL-1β, TNF-α and IFNγ and assayed for apoptosis, nitric oxide (NO) generation and insulin secretion. Activation of signalling pathways, apoptosis and endoplasmic reticulum (ER) stress were determined by immunoblotting. Stabilisation of mRNA transcripts was measured by RT-PCR following transcriptional arrest. Mice were injected with multiple low doses of streptozotocin (MLD-STZ) and fasting blood glucose monitored.

Results

Deletion of Prkcd inhibited apoptosis and NO generation in islets stimulated ex vivo with cytokines. It also delayed the onset of hyperglycaemia in MLD-STZ-treated mice. Activation of ERK, p38, JNK, AKT1, the ER stress markers DDIT3 and phospho-EIF2α and the intrinsic apoptotic markers BCL2 and MCL1 was not different between genotypes. However, deletion of Prkcd destabilised mRNA transcripts for Nos2, and for multiple components of the toll-like receptor 2 (TLR2) signalling complex, which resulted in disrupted TLR2 signalling.

Conclusions/interpretation

Loss of PKCδ partially protects against hyperglycaemia in the MLD-STZ model in vivo, and against cytokine-mediated apoptosis in vitro. This is accompanied by reduced NO generation and destabilisation of Nos2 and components of the TLR2 signalling pathway. The results highlight a mechanism for regulating proinflammatory gene expression in beta cells independently of transcription.

Available only for authorised users

Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115–2133CrossRefPubMed

Mathis D, Vence L, Benoist C (2001) β-Cell death during progression to diabetes. Nature 414:792–798CrossRefPubMed

McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA (1996) Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 211:24–32PubMed

Thomas HE, McKenzie MD, Angstetra E, Campbell PD, Kay TW (2009) Beta cell apoptosis in diabetes. Apoptosis 14:1389–1404CrossRefPubMed

Eizirik DL, Sandler S, Welsh N, Juntti-Berggren L, Berggren PO (1995) Interleukin-1 β-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation. Mol Cell Endocrinol 111:159–165CrossRefPubMed

Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332:281–292PubMed

Carpenter L, Cordery D, Biden TJ (2001) Protein kinase Cδ activation by interleukin-1β stabilizes inducible nitric-oxide synthase mRNA in pancreatic β-cells. J Biol Chem 276:5368–5374CrossRefPubMed

Carpenter L, Cordery D, Biden TJ (2002) Inhibition of protein kinase C δ protects rat INS-1 cells against interleukin-1β and streptozotocin-induced apoptosis. Diabetes 51:317–324CrossRefPubMed

Brodie C, Blumberg PM (2003) Regulation of cell apoptosis by protein kinase c δ. Apoptosis 8:19–27CrossRefPubMed

10.

Jackson DN, Foster DA (2004) The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival. FASEB J 18:627–636CrossRefPubMed

11.

Reyland ME (2007) Protein kinase Cδ and apoptosis. Biochem Soc Trans 35:1001–1004CrossRefPubMed

12.

Hennige AM, Ranta F, Heinzelmann I et al (2010) Overexpression of kinase negative protein kinase Cδ in pancreatic β-cells protects from diet-induced glucose intolerance and β-cell dysfunction. Diabetes 59:119–127CrossRefPubMed

13.

Qi X, Mochly-Rosen D (2008) The PKCδ–Abl complex communicates ER stress to the mitochondria—an essential step in subsequent apoptosis. J Cell Sci 121:804–813CrossRefPubMed

14.

Akerfeldt MC, Howes J, Chan JY et al (2008) Cytokine-induced β-cell death is independent of endoplasmic reticulum stress signaling. Diabetes 57:3034–3044CrossRefPubMed

15.

Chambers KT, Unverferth JA, Weber SM, Wek RC, Urano F, Corbett JA (2008) The role of nitric oxide and the unfolded protein response in cytokine-induced β-cell death. Diabetes 57:124–132CrossRefPubMed

16.

Kharroubi I, Ladriere L, Cardozo AK, Dogusan Z, Cnop M, Eizirik DL (2004) Free fatty acids and cytokines induce pancreatic β-cell apoptosis by different mechanisms: role of nuclear factor-kB and endoplasmic reticulum stress. Endocrinology 145:5087–5096CrossRefPubMed

17.

Wang Q, Zhang H, Zhao B, Fei H (2008) IL-1β caused pancreatic β-cells apoptosis is mediated in part by endoplasmic reticulum stress via the induction of endoplasmic reticulum Ca(2+) release through the c-Jun N-terminal kinase pathway. Mol Cell Biochem 324:183–190CrossRefPubMed

18.

Tonnesen MF, Grunnet LG, Friberg J et al (2009) Inhibition of nuclear factor-κB or Bax prevents endoplasmic reticulum stress- but not nitric oxide-mediated apoptosis in INS-1E cells. Endocrinology 150:4094–4103CrossRefPubMed

19.

Cardozo AK, Ortis F, Storling J et al (2005) Cytokines downregulate the sarcoendoplasmic reticulum pump Ca²⁺ ATPase 2b and deplete endoplasmic reticulum Ca²⁺, leading to induction of endoplasmic reticulum stress in pancreatic β-cells. Diabetes 54:452–461CrossRefPubMed

20.

Eizirik DL, Cardozo AK, Cnop M (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29:42–61CrossRefPubMed

21.

Scheuner D, Kaufman RJ (2008) The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes. Endocr Rev 29:317–333CrossRefPubMed

22.

Leitges M, Mayr M, Braun U et al (2001) Exacerbated vein graft arteriosclerosis in protein kinase Cδ-null mice. J Clin Invest 108:1505–1512PubMed

23.

Frangioudakis G, Burchfield JG, Narasimhan S et al (2009) Diverse roles for protein kinase C δ and protein kinase C ε in the generation of high-fat-diet-induced glucose intolerance in mice: regulation of lipogenesis by protein kinase C δ. Diabetologia 52:2616–2620CrossRefPubMed

24.

Miyamoto A, Nakayama K, Imaki H et al (2002) Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 416:865–869CrossRefPubMed

25.

Comens PG, Wolf BA, Unanue ER, Lacy PE, McDaniel ML (1987) Interleukin 1 is potent modulator of insulin secretion from isolated rat islets of Langerhans. Diabetes 36:963–970CrossRefPubMed

26.

Sandler S, Andersson A, Hellerstrom C (1987) Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 121:1424–1431CrossRefPubMed

27.

Ammendrup A, Maillard A, Nielsen K et al (2000) The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic β-cells. Diabetes 49:1468–1476CrossRefPubMed

28.

Larsen CM, Wadt KA, Juhl LF et al (1998) Interleukin-1β-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Biol Chem 273:15294–15300CrossRefPubMed

29.

Chen N, Ma W, Huang C, Dong Z (1999) Translocation of protein kinase Cε and protein kinase Cδ to membrane is required for ultraviolet B-induced activation of mitogen-activated protein kinases and apoptosis. J Biol Chem 274:15389–15394CrossRefPubMed

30.

Schultz H, Engel K, Gaestel M (1997) PMA-induced activation of the p42/44ERK- and p38RK-MAP kinase cascades in HL-60 cells is PKC dependent but not essential for differentiation to the macrophage-like phenotype. J Cell Physiol 173:310–318CrossRefPubMed

31.

Storling J, Binzer J, Andersson AK et al (2005) Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 48:2039–2050CrossRefPubMed

32.

Dickson LM, Rhodes CJ (2004) Pancreatic β-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am J Physiol Endocrinol Metab 287:E192–198CrossRefPubMed

33.

Oyadomari S, Koizumi A, Takeda K et al (2002) Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 109:525–532PubMed

34.

Sitailo LA, Tibudan SS, Denning MF (2006) The protein kinase C δ catalytic fragment targets Mcl-1 for degradation to trigger apoptosis. J Biol Chem 281:29703–29710CrossRefPubMed

35.

van de Casteele M, Kefas BA, Ling Z, Heimberg H, Pipeleers DG (2002) Specific expression of Bax-ω in pancreatic β-cells is down-regulated by cytokines before the onset of apoptosis. Endocrinology 143:320–326CrossRefPubMed

36.

Doller A, Akool ES, Huwiler A et al (2008) Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cδ elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 28:2608–2625CrossRefPubMed

37.

Gringhuis SI, Garcia-Vallejo JJ, van Het Hof B, van Dijk W (2005) Convergent actions of IκB kinase β and protein kinase Cδ modulate mRNA stability through phosphorylation of 14-3-3β complexed with tristetraprolin. Mol Cell Biol 25:6454–6463CrossRefPubMed

38.

Lgssiar A, Hassan M, Schott-Ohly P et al (2004) Interleukin-11 inhibits NF-κB and AP-1 activation in islets and prevents diabetes induced with streptozotocin in mice. Exp Biol Med Maywood 229:425–436PubMed

39.

Li Z, Karlsson FA, Sandler S (2000) Islet loss and alpha cell expansion in type 1 diabetes induced by multiple low-dose streptozotocin administration in mice. J Endocrinol 165:93–99CrossRefPubMed

40.

Carpenter L, Mitchell CJ, Xu ZZ, Poronnik P, Both GW, Biden TJ (2004) PKCα is activated but not required during glucose-induced insulin secretion from rat pancreatic islets. Diabetes 53:53–60CrossRefPubMed

41.

Jones PM, Persaud SJ (1998) Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic β-cells. Endocr Rev 19:429–461CrossRefPubMed

42.

Schmitz-Peiffer C, Biden TJ (2008) Protein kinase C function in muscle, liver, and β-cells and its therapeutic implications for type 2 diabetes. Diabetes 57:1774–1783CrossRefPubMed

43.

Uchida T, Iwashita N, Ohara-Imaizumi M et al (2007) PKC-δ plays non-redundant role in insulin secretion in pancreatic β cells. J Biol Chem 282:2707–2716CrossRefPubMed

44.

Kroncke KD, Fehsel K, Sommer A, Rodriguez ML, Kolb-Bachofen V (1995) Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem Hoppe-Seyler 376:179–185PubMed

45.

Oyadomari S, Takeda K, Takiguchi M et al (2001) Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci USA 98:10845–10850CrossRefPubMed

46.

Boni-Schnetzler M, Boller S, Debray S et al (2009) Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150:5218–5229CrossRefPubMed

47.

Kim HS, Han MS, Chung KW et al (2007) Toll-like receptor 2 senses β-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27:321–333CrossRefPubMed

48.

Ehses JA, Meier DT, Wueest S et al (2010) Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 53:1795–1806CrossRefPubMed

49.

Eberhardt W, Doller A, Akool ES, Pfeilschifter J (2007) Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther 114:56–73CrossRefPubMed

50.

Stoecklin G, Anderson P (2006) Posttranscriptional mechanisms regulating the inflammatory response. Adv Immunol 89:1–37CrossRefPubMed

Title: Deletion of protein kinase Cδ in mice modulates stability of inflammatory genes and protects against cytokine-stimulated beta cell death in vitro and in vivo
Authors: J. Cantley
E. Boslem
D. R. Laybutt
D. V. Cordery
G. Pearson
L. Carpenter
M. Leitges
T. J. Biden
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 2/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1962-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 2/2011

Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort

Immortal time bias does not invalidate the association of self-monitoring of blood glucose with better survival of patients with type 2 diabetes in the epidemiological study ROSSO (Retrolective Study: Self-monitoring of Blood Glucose and Outcome in Patients with Type 2 Diabetes)

Tissue-specific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db/db mice as a model of type 2 diabetes

Comparison of two sulfonylureas with high and low myocardial KATP channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes

Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort

Rosiglitazone: a European regulatory perspective

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials